|Awarded On||November 02, 2011|
|Title||Clinical Translation of Therapeutic siRNA in Solid Malignancies|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Robert L Coleman|
|Cancer Sites||All Sites, Ovary|
Ovarian cancer remains the deadliest of all gynecologic malignancies. More than 75% of women diagnosed with the disease have advanced stage, for which, the majority develop recurrence. Tragically, recurrent disease is rarely (<1%) cured despite surgical and pharmacological interventions (including biologically-targeted agents), which is driving the need for innovative and novel therapeutic approaches. RNA interference (RNAi) is a normal regulatory process by which individual cells control the functionality of genes by producing short RNA fragments (siRNA) which, when bound, can cause gene repression or degradation. We have developed a systemically deliverable siRNA therapeutic (Epharna™),...